OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis $0.09 +0.00 (+2.27%) As of 08/29/2025 03:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enzon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.08▼$0.0950-Day Range$0.06▼$0.1352-Week Range$0.06▼$0.24Volume41,640 shsAverage Volume26,653 shsMarket Capitalization$6.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey. Read More Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENZN Stock News HeadlinesEnzon Pharmaceuticals, Inc. (ENZN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comEnzon Pharmaceuticals (ENZN) Merges with Viskase CompaniesJune 21, 2025 | gurufocus.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.September 1 at 2:00 AM | InvestorPlace (Ad)Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger AgreementJune 21, 2025 | finanznachrichten.deEnzon to merge with Viskase in all stock dealJune 21, 2025 | msn.comEnzon and Viskase Enter into Merger AgreementJune 20, 2025 | globenewswire.comENZN Enzon Pharmaceuticals, Inc.May 30, 2025 | seekingalpha.comEnzon Pharmaceuticals Expands Board and Forms Strategic CommitteeJanuary 10, 2025 | tipranks.comSee More Headlines ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed this year? Enzon Pharmaceuticals' stock was trading at $0.1561 at the beginning of 2025. Since then, ENZN shares have decreased by 42.3% and is now trading at $0.09. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) announced its quarterly earnings results on Thursday, August, 14th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings8/14/2025Today9/01/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear Founded1981Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$780 thousand Net MarginsN/A Pretax Margin1,150.00% Return on Equity-91.38% Return on Assets-4.03% Debt Debt-to-Equity RatioN/A Current Ratio55.71 Quick Ratio55.71 Sales & Book Value Annual Sales$30 thousand Price / Sales222.65 Cash Flow$0.01 per share Price / Cash Flow8.59 Book Value$0.04 per share Price / Book2.25Miscellaneous Outstanding Shares74,215,000Free Float73,918,000Market Cap$6.68 million OptionableNot Optionable Beta0.34 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:ENZN) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENZN Stock Alerts